From The Drugbank Application To The Novel Drugs: A Pharmacogenomic Summary Setya Rini Abiyana1, Setiyo Budi Santoso1, Imron Wahyu Hidayat1, Ratna Wijayatri1, Alfian Syarifuddin1,
1Department of Pharmacy, Universitas Muhammadiyah Magelang, Indonesia
Abstract
Due to reduced risks, time, cost, and resource requirements compared to conventional experimental procedures, computational drug development has gained relevance in recent decades. The DrugBank application has expanded the number and quality of pharmacological activity and drug metabolic pathways depicted visually. Our review elaborated a number of novel drugs and the molecular target mechanisms discovered with DrugBank. The study involves literatures indexed by Scopus and Pub Med, the search uses a combination of the following keyword variants- ^Drugbank AND Repurposing Drug^, ^Drugbank AND Pharmacogenomic^. This study only used original articles in english which were peer reviewed journals published from October 2020 to November 2022. Thus, the screening results of library sources were narrowed to 9 original articles papers that met the inclusion criteria. Our result highlighted the involvement of twenty-three drug-targeting molecules in nine spesific diseases. We discovered that the molecules listed below have been found to be key targets of therapeutic activity in cancer patients, including ACK 1, HMGA 1, PSAT 1, ESR1,UQCRH, GSTM3, FGFR2, PGD, NR1H3. On the other side, IL6R has been linked to asthma and depression, while the depression treatment has also been linked to Angiotensin II, AT1R, and AT2R interventions. Last, JAK 1, IL13, IL4, IL6R, and IL1B were the primary targets of ruling drugs on atopic dermatitis, whereas CD 80 DNA, and CD 86 were the main target in the drug discovery of multiple sclerosis therapies. Our pathway offers new perspectives on the research of discovering novel drugs and reliable foundation for advanced explanation on clinical investigations.
